OR WAIT null SECS
Orrin Troum, MD: Accurately Imaging Gout With DECT Scanning
Troum discussed the AGILE study and how DECT scanning helped visualize improvements in uncontrolled gout.
Shortened infusion times of pegloticase (Krystexxa; Amgen) may reduce the treatment burden for patients with uncontrolled gout in new research which found 1-hour infusions to be well-tolerated.
Orrin Troum, MD, clinical professor of medicine, Keck School of Medicine, University of Southern California, and director, clinical rheumatology research, Providence St John's Hospital, Santa Monica, California, presented data from the phase 4 AGILE study evaluating shortened infusions at last month’s American College of Rheumatology (ACR) Convergence 2024 in Washington, DC.
HCPLive® spoke with Troum to learn more about gout management and how shortened infusion times can help reduce patients’ treatment burdens. He also discussed autoimmune investigations he is involved in at Providence St John's, including indications such as lupus, Sjogren disease, and psoriatic arthritis.
Troum emphasized the value of dual-energy computed tomography (DECT) scans in managing gout and the importance of expanding the access of use of DECT scans, which are not available for rheumatologists in all areas.
“By DECT scanning, you can get a very clear picture with over 90% accuracy with being specific and sensitive to identifying urate crystals, and that has been a big help to me, because it helps us in targeting patients, specifically with tophaceous gout that we can measure… and by the end of Krystexxa therapy, they don't have anymore. So that's really a very good outcome for me that I've used… Not everybody has access to it, but [it’s been a] very useful tool for me,” Troum said.
Relevant disclosures for Troum include AbbVie/Abbott, Amgen, Bristol-Myers Squibb, Eli Lilly, Genentech, GlaxoSmithKlein, Novartis, Roche, and UCB.
